RxSight, Inc. (RXST)
Market Cap | 325.10M |
Revenue (ttm) | 148.31M |
Net Income (ttm) | -26.55M |
Shares Out | 40.64M |
EPS (ttm) | -0.67 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 2,222,234 |
Open | 8.33 |
Previous Close | 8.46 |
Day's Range | 7.85 - 8.50 |
52-Week Range | 6.32 - 58.23 |
Beta | 1.21 |
Analysts | Hold |
Price Target | 19.40 (+142.5%) |
Earnings Date | Aug 7, 2025 |
About RXST
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company’s RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response to specific patterns of ultraviolet, which can be... [Read more]
Financial Performance
In 2024, RxSight's revenue was $139.93 million, an increase of 57.09% compared to the previous year's $89.08 million. Losses were -$27.46 million, -43.52% less than in 2023.
Financial StatementsAnalyst Summary
According to 11 analysts, the average rating for RXST stock is "Hold." The 12-month stock price target is $19.4, which is an increase of 142.50% from the latest price.
News

Johnson Fistel Begins Investigation on Behalf of RxSight, Inc. (RXST) Shareholders
SAN DIEGO, July 11, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP is investigating whether RxSight, Inc. (NASDAQ: RXST), or any of its executive officers, violated federal ...

Crude Oil Moves Higher; RxSight Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

Aehr Test Systems Posts Downbeat Sales, Joins RxSight, Vertical Aerospace And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures gaining around 0.1% on Wednesday.

RxSight, Inc. Announces Preliminary Second Quarter 2025 Revenue and Revised 2025 Guidance
ALISO VIEJO, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

RxSight: Valuation Blowout Creates Opportunity
RxSight is a promising growth stock in the medical device sector, focusing on innovative cataract treatments with a large addressable market. Despite a recent decline, RxSight's high margins and scala...

RxSight, Inc. to Participate in the Stifel 2025 Virtual Ophthalmology Forum
ALISO VIEJO, Calif., May 20, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

Top 3 Health Care Stocks That Are Preparing To Pump This Quarter
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

RxSight, Inc. (RXST) Q1 2025 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President & Chief Executive...

RxSight, Inc. to Present at the Bank of America Healthcare Conference
ALISO VIEJO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients followin...

RxSight: Navigating Market Headwinds Amid Intensifying Competition (Downgrade)
RxSight posted a sequential revenue decline, revealing cracks in momentum despite earlier signs of profitability. Revised 2025 outlook and lack of expected profitability suggest earlier optimism was p...

RxSight, Inc. (RXST) Q1 2025 Preliminary Results Conference Call (Transcript)
RxSight, Inc. (NASDAQ:RXST) Q1 2025 Preliminary Results Conference Call April 3, 2025 8:00 AM ET Company Participants Oliver Moravcevic - VP, IR Dr. Ron Kurtz - Director, Co-President and CEO Shelley...

RxSight, Inc. Announces Preliminary First Quarter 2025 Revenue and Revised 2025 Guidance
ALISO VIEJO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following...

RxSight, Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference
ALISO VIEJO, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients followin...

RxSight, Inc. (RXST) Q4 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q4 2024 Earnings Conference Call February 25, 2025 4:30 PM ET Company Participants Oliver Moravcevic - VP, IR Ron Kurtz - President and CEO Shelley Thunen - CFO Conference...

RxSight, Inc. Reports Fourth Quarter and Full-Year 2024 Financial Results, Reaffirms 2025 Guidance
ALISO VIEJO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...

RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Financial and Operational Results and 2025 Guidance
ALISO VIEJO, Calif., Jan. 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference
ALISO VIEJO, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

RxSight's Momentum In The Large Cataract Surgery Market Merits A Close Eye
RxSight's light adjustable lenses [LAL] continue to gain traction in the $6 billion-plus cataract surgical market. In their Q3 earnings report, RxSight announced that 24,554 LALs were sold in Q3, repr...

RxSight, Inc. (RXST) Q3 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Oliver Moravcevic - Vice President, Investor Relations Ron Kurtz - President, Chief Execu...

RxSight, Inc. to Report Third Quarter Financial Results on November 7, 2024
ALISO VIEJO, Calif., Oct. 24, 2024 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery,...

RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences
ALISO VIEJO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

Investing In The Future Of Cataract Surgery: The RxSight Advantage
RxSight, Inc. is transforming cataract surgery with the Light Adjustable Lens system, offering postoperative customization for superior vision outcomes. The global cataract devices market is rapidly e...

RxSight, Inc. (RXST) Q2 2024 Earnings Call Transcript
RxSight, Inc. (NASDAQ:RXST) Q2 2024 Earnings Conference Call August 5, 2024 4:30 PM ET Company Participants Ron Kurtz - President, Chief Executive Officer Shelley Thunen - Assistant Secretary, Chief ...

RxSight, Inc. Reports Second Quarter 2024 Financial Results
ALISO VIEJO, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...

RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024
ALISO VIEJO, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RXST) – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following ...